219 related articles for article (PubMed ID: 23534533)
1. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
Rosenmann H
Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H
Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729
[TBL] [Abstract][Full Text] [Related]
3. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.
Rozenstein-Tsalkovich L; Grigoriadis N; Lourbopoulos A; Nousiopoulou E; Kassis I; Abramsky O; Karussis D; Rosenmann H
Exp Neurol; 2013 Oct; 248():451-6. PubMed ID: 23876516
[TBL] [Abstract][Full Text] [Related]
4. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
6. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
Madav Y; Wairkar S; Prabhakar B
Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
[TBL] [Abstract][Full Text] [Related]
7. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
8. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
Sigurdsson EM
Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
[TBL] [Abstract][Full Text] [Related]
9. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
10. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
11. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the development of immunotherapies for tauopathies.
Ubhi K; Masliah E
Exp Neurol; 2011 Aug; 230(2):157-61. PubMed ID: 20970422
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for tauopathies.
Gu J; Sigurdsson EM
J Mol Neurosci; 2011 Nov; 45(3):690-5. PubMed ID: 21739165
[TBL] [Abstract][Full Text] [Related]
14. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
15. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson EM
J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
[TBL] [Abstract][Full Text] [Related]
17. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
18. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
20. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
